DiChe Pharmaceuticals (688192.SH): Sulforaphane has shown strong and long-lasting anti-tumor effects and good safety in the treatment of advanced non-small cell lung cancer.

Di Zhe Pharmaceutical (688192.SH) announced that recently, the company presented the latest data from the international multicenter registration clinical study "Wu-Kong1B" of Shuwote (generic name: Shuwotinib tablets) at the 2024 European Society for Medical Oncology (ESMO) Congress, with over 40% of non-Asian patients represented in the global subgroup. The study results showed that Shuwote demonstrated strong and durable anti-tumor effectiveness and good safety for patients with EGFR 20 exon insertion mutations (Exon20ins) in non-small cell lung cancer (NSCLC), regardless of the patient's mutation subtype, race, region, baseline brain metastasis, or prior treatment with EGFR monoclonal antibodies or immunotherapy. The results of the study are representative on a global scale.